

Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia

CBH is committed to ensuring members receive quality care. This measure assesses the percentage of members ages 18 to 64 years of age with schizophrenia and cardiovascular disease who had an LDL-C test during the measurement year (January 1 to December 31). Cardiovascular disease is the leading cause of death in the United States, disproportionately affecting members with Schizophrenia. Members with Schizophrenia die 10 to 20 years earlier than the general population, most often from cardiovascular disease. For these reasons, it is important to screen for and monitor existing cardiovascular disease.

References:

Kochanek, KD, Xu JQ, Arias E. Mortality in the United States, 2019. NCHS Data Brief. No395. Hyattsville, MD: National Center for Health Statistics. 2020.

Olfson, M, Gerhard, T, Huang, C, Crystal, S, Stroup, T. Premature Mortality Among Adults with Schizophrenia in the United States. JAMA Psychiatry. 2015; 72(12):1172-81.

Liu et al., 207.

Best Practices

- ➔ Screen members for cardiovascular disease using an LDL-C test at least annually, particularly those who do not have regular contact with a primary care physician (PCP).
- ➔ Educate member and caregiver about:
 - » The risks associated with antipsychotic medications and cardiovascular disease
 - » The importance of obtaining an LDL-C test
 - » The importance of a healthy lifestyle
- ➔ Assess need for case management services and refer accordingly.
- ➔ Discuss results with members and refer to PCP as appropriate.
- ➔ Collaborate with case management and PCPs on member care strategies. Ensure the results are communicated in a timely fashion to other health care providers involved in the care of the member.
- ➔ Screen member for tobacco use and offer tobacco use counseling and pharmacotherapy. Refer to [CBH's Clinical Practices Guidelines for Tobacco Use Disorder](#)

Schizophrenia Diagnoses Associated with this Measure

- [F20.0] Paranoid Schizophrenia
- [F20.1] Disorganized Schizophrenia
- [F20.2] Catatonic Schizophrenia
- [F20.3] Undifferentiated Schizophrenia
- [F20.5] Residual Schizophrenia
- [F20.81] Schizophreniform Disorder
- [F20.89] Other Schizophrenia
- [F20.9] Schizophrenia, Unspecified
- [F25.0] Schizoaffective Disorder, Bipolar Type
- [F25.1] Schizoaffective Disorder, Depressive Type
- [F25.8] Other Schizoaffective Disorders
- [F25.9] Schizoaffective Disorder, Unspecified

Lab Screenings Associated with this Measure

LDL-C Test

- ➔ CPT: 80061, 83700, 83701, 83704, 83721

Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia

Resources

- ➔ [CBH: HEDIS Tip Sheets](#)
- ➔ [CBH: Clinical Practices Guidelines for Tobacco Use Disorder](#)
- ➔ [CBH: Pharmacy Resources for Members](#)
- ➔ [NCQA Letter: NCQA Supports Medicaid Behavioral Measure Reporting](#)
- ➔ [CBH: Pharmacy Resources for Providers](#)
- ➔ [Centers for Medicare and Medicaid Services \(CMS\): Measures Inventory Tool](#)
- ➔ [CBH: Integrated Care Plan Resources for Members](#)

Screening Recommendations Based on [APA Clinical Practice Guideline for the Treatment of Patients with Schizophrenia](#)

| Parameter | Suggested Frequency |
|------------------------------|--|
| Hyperlipidemia (lipid panel) | Lipid panel at 4 months after initiating a new antipsychotic medication and at least annually thereafter |

Lab Coverage Information

| Health Plan | Laboratory Provider |
|---|--|
| Community Behavioral Health | Atlantic Diagnostic Laboratories Parkway Clinical Laboratories |
| Jefferson Health Plans | Quest Diagnostics |
| Keystone First | LabCorp |
| United Healthcare | LabCorp Quest Diagnostics |
| Gelsinger | LabCorp Quest Diagnostics Jefferson Health |
| PA Health and Wellness | LabCorp Quest Diagnostics |
| UPMC | Quest Diagnostics |

Disclaimer: The information contained in this tip sheet is for educational and informational purposes only. The clinical services described in this tip sheet may not be covered for all CBH enrollees. To find out about what services are available to you under the CBH benefit package, please contact CBH Provider Operations at 215-413-3100.